Treatment for Carbapenem-Resistant Escherichia coli Infections

First-Line Treatment Options

Ceftazidime-avibactam 2.5 g IV q8h is the preferred first-line treatment for carbapenem-resistant E. coli bloodstream infections, with a recommended treatment duration of 7-14 days, individualized based on clinical response 1
Meropenem-vaborbactam 4 g IV q8h is an alternative option for carbapenem-resistant E. coli infections if available 1
Imipenem-cilastatin-relebactam 1.25 g IV q6h can be considered if the first two options are unavailable for treating carbapenem-resistant E. coli infections 1
Ceftazidime-avibactam 2.5 g IV q8h remains the preferred treatment for respiratory infections caused by carbapenem-resistant E. coli, with prolonged infusion (3 hours) and appropriate renal adjustment associated with improved 30-day survival 1, 3

For severe carbapenem-resistant E. coli infections (sepsis/septic shock), combination therapy with polymyxin-based combinations, such as colistin and tigecycline, is recommended to improve survival outcomes 1
Colistin 5 mg CBA/kg IV loading dose, then 2.5 mg CBA (1.5 CrCl + 30) IV q12h + Tigecycline 100 mg IV loading dose, then 50 mg IV q12h can be used as a combination therapy for severe carbapenem-resistant E. coli infections 1
Ceftazidime-avibactam combined with aztreonam is suggested as a preferential choice for metallo-β-lactamase-producing CRE, with lower 30-day mortality (19.2% vs 44%) and lower clinical treatment failure compared to other active antimicrobial agents 2

Always perform susceptibility testing to guide therapy, especially for determining MICs to carbapenems, and consider high-dose extended-infusion meropenem when MICs are ≤8 mg/L 3, 5
Determine the carbapenemase type (KPC, NDM, OXA-48, etc.) whenever possible to guide optimal therapy for carbapenem-resistant E. coli infections 2
Double carbapenem therapy (typically ertapenem plus another carbapenem) may be considered for highly resistant strains when other options are limited, with some observational studies suggesting improved survival in patients with invasive KPC infections 3

Follow-up cultures are recommended in case of treatment failure to detect resistance development in carbapenem-resistant E. coli infections 5
Optimal antibiotic dosing schemes should be used, with attention to adverse effects, especially with polymyxins and aminoglycosides, and source control should always be a priority to optimize outcomes and shorten antibiotic treatment durations 5